Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18814665 | 0.89 | GAA (0.49) | GAAL3MBTL1TSHRHTTMAPT | |
| SCHEMBL18814668 | 0.89 | GAA (0.49) | GAATSHRHTTMAPTLMNA | |
| SCHEMBL16906331 | 0.89 | HSD17B10 (0.49) | GAAL3MBTL1TSHRHTTMAPT | |
| SCHEMBL29676217 | 0.87 | KCNN4 (0.50) | GAAL3MBTL1TSHRHTTMAPT | |
| SCHEMBL20738625 | 0.87 | USP36 (0.49) | GAAL3MBTL1LMNAALDH1A1 | |
| SCHEMBL20738592 | 0.87 | KCNN4 (0.50) | GAAL3MBTL1TSHRHTTMAPT | |
| SCHEMBL2283304 | 0.85 | SSTR4 (0.51) | GAATSHRMAPTACACB | |
| SCHEMBL8930633 | 0.84 | L3MBTL1 (0.67) | L3MBTL1TSHRHTTMAPTLMNA | |
| SCHEMBL29675690 | 0.84 | ALDH1A1 (0.51) | HTTMAPTLMNAALDH1A1 | |
| SCHEMBL12731609 | 0.84 | GAA (0.44) | GAAL3MBTL1TSHRHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12034115-B2 | Solid electrolyte composition, sheet for all-solid state secondary battery, electrode sheet for all-solid state secondary battery, and all-solid state secondary battery | FUJIFILM CORPORATION (JP) | 2024-07-09 | — | — | US | disclosed |
| US-20240213479-A1 | ELECTRODE COMPOSITION, ELECTRODE SHEET FOR ALL-SOLID STATE SECONDARY BATTERY, ALL-SOLID STATE SECONDARY BATTERY, AND MANUFACTURING METHODS FOR ELECTRODE COMPOSITION, ELECTRODE SHEET FOR ALL-SOLID STATE SECONDARY BATTERY, AND ALL-SOLID STATE SECONDARY BATTERY | FUJIFILM CORPORATION (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20190344483-A1 | RESIN-SEALED COMPONENT AND METHOD FOR PRODUCING SAME | DENSO CORPORATION (JP) | 2019-11-14 | — | — | US | disclosed |
| US-9593197-B2 | Trigger-responsive chain-shattering polymers | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-03-14 | — | — | US | disclosed |
| EP-2325167-A1 | METHOD FOR PRODUCING CARBAMATE COMPOUND | Ube Industries, Ltd. (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312217-A1 | Organic Compounds | TRPA1, TRPV1, CHRM1 | GAA 3452/4885L3MBTL1 1412/4885TSHR 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.